Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V0KJ
|
||||
| Former ID |
DCL001110
|
||||
| Drug Name |
IDDBCP161883
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 3 | [1] | ||
| Company |
Mitsubishi Tanabe
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | Inhibitor | [2], [3] | |
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01798238) Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | ||||
| REF 2 | Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. | ||||
| REF 3 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.